Core Viewpoint - The recent focus on Haohai Biological Technology is the shareholder's plan to reduce holdings, which may exert short-term pressure on market sentiment but aligns with previous commitments made by the shareholder [1] Stock Performance - Haohai Biological Technology's A-shares (688366.SH) have shown weak performance, closing at 45.91 yuan on February 13, 2026, down 1.21% for the day and a cumulative decline of 2.28% over the past five days; meanwhile, the Hong Kong shares (06826.HK) closed at 26.72 HKD, up 2.06% for the day but with a volatility of 4.55% over the same period [2] - On February 13, 2026, net outflow of approximately 1 million yuan was observed in A-shares, indicating short-term pressure on capital [2] - The A-share price has fallen below the 5-day moving average (46.22 yuan), with a MACD indicator showing a death cross signal; the Hong Kong stock is near the middle band of the Bollinger Bands (26.034 HKD), with the KDJ indicator showing a J line at 78.96, indicating short-term overbought conditions [2] Financial Report Analysis - In Q3 2025, the company experienced a decline in performance, with quarterly revenue decreasing by 11.29% to 595 million yuan and net profit attributable to shareholders dropping by 11.39% to 93.58 million yuan; cumulative revenue for the first three quarters fell by 8.47%, and net profit decreased by 10.63% [3] - The gross margin remained at 70.39%, but the non-recurring net profit saw a significant decline of 44.54%, primarily due to increased sales expenses and market environment impacts [3] Institutional Perspectives - Institutions maintain a long-term focus on Haohai Biological Technology's fundamentals, with two institutions issuing buy or hold ratings for the Hong Kong shares in February 2026, targeting an average price of 56.65 HKD, indicating potential upside compared to the current stock price [4] - Institutions are particularly attentive to the company's progress in exporting medical devices and high-end product lines, although the short-term reduction in holdings may suppress valuation recovery [4]

以上内容基于公开资料整理，不构成投资建议。 昊海生科 昊海生物科技 分时图 日K线 周K线 月K线 46.13 -0.34 -0.73% 0.77% 0.52% 0.26% 0.00% 0.26% 0.52% 0.77% 46.11 46.23 46.35 46.47 46.59 46.71 46.83 09:30 10:30 11:30/13:00 14:00 15:00 15:30 0 8152 2万 2万 经济观察网2026年2月12日，昊海生科发布公告称，股东楼国梁因自身资金需要，计划通过集中竞价和 大宗交易方式减持不超过100万股公司股份，占公司总股本的比例不超过0.4337%。截至公告日，楼国 梁持有公司股份约712万股，持股比例为3.0882%。该减持计划自公告披露后3个交易日起的3个月内实 施，可能对短期市场情绪构成压力。 股票近期走势 受股东减持公告影响，昊海生科股价近期表现偏弱。截至2026年2月13日开盘，股价报46.47元，近5日 累计下跌1.09%。2月12日单日下跌0.81%，成交额约1978.85万元，主力资金净流出6.53万元，显示短期 资金面承压。同期，医药生物板块整体微跌0 ...

Group 1 - Major shareholder Han Yuanfu of Dayuan Pump Industry plans to reduce his stake by up to 3%, totaling no more than 5.595 million shares [1] - Hainan Highway, a shareholder of Haikou Group, intends to increase its stake in the company by no less than 40 million yuan and no more than 50 million yuan [2] - China Communications Construction Company signed new contracts worth 1.883672 trillion yuan in 2025, a year-on-year increase of 0.13% [3] Group 2 - The controlling shareholder of Quzhou Development proposed to repurchase shares worth between 100 million and 200 million yuan [4] - Shareholder Huang Song of Huibo Pu plans to reduce his stake by up to 1%, totaling no more than 1.3372 million shares [5] - The board secretary of Fusenmei has had his detention lifted and is now under investigation, allowing him to resume his duties [6] Group 3 - YN Holdings clarified that its investment target does not belong to the sectors of computing chip manufacturing, computing leasing, or cloud services [7] - Shareholder Euro Star Diamond plans to reduce its stake in Laishen Tongling by up to 3%, totaling no more than 1.029 million shares [8] - Shareholder Zhu Guangkui of Demar Technology plans to reduce his stake by up to 3%, totaling no more than 791.24 million shares [10] Group 4 - Newnow's subsidiary received approval for clinical trials of drug SYS6023 for breast cancer treatment [11] - Ruipubio plans to invest 295 million yuan to establish a merger and acquisition industry fund focusing on animal health and biomedicine [12] - Shareholder Ningbo Hutong plans to reduce its stake in Huitong Energy by up to 1%, totaling no more than 206.28 million shares [13] Group 5 - Chengda Bio's high-dose influenza virus vaccine has received approval for clinical trials [14] - Kang En Bei's subsidiaries participated in the national centralized procurement process, with selected drugs expected to generate 385 million yuan in sales in 2024 [15] - Weitang Industrial signed a strategic cooperation framework agreement with Amphenol to enhance product development and market collaboration [16] Group 6 - Terui De is the first candidate for a 137 million yuan EPC general contracting project [17] - Chen Zhan Optoelectronics plans to invest 650 million yuan to establish an overseas smart manufacturing base [19] - Zhang Yi Technology's AI short drama business revenue is expected to account for no more than 1% of total revenue in 2025 [20] Group 7 - Jiangshan Co. plans to reduce its stake by up to 3%, totaling no more than 4.3308 million shares [21] - Xie Chuang Data plans to procure servers from multiple suppliers, with a total expected expenditure of no more than 11 billion yuan [22] - Huaming Equipment is planning to issue H-shares and list on the Hong Kong Stock Exchange [23] Group 8 - Wenzhou Hongfeng plans to raise no more than 450 million yuan through a private placement for expansion projects [24] - Yingkerui plans to raise no more than 379 million yuan for various projects including smart power supply systems [25] - Jingrui Electric Materials plans to invest 600 million yuan to build a key materials base for the integrated circuit manufacturing industry [26] Group 9 - Beijing Bank's chairman resigned due to age [27] - Youkeshu's actual controller plans to increase his stake by no less than 50 million yuan and no more than 100 million yuan [28] - Hanbo High-tech's subsidiary plans to acquire assets to enter the wet electronic chemicals industry [29] Group 10 - Jia Mei Packaging clarified that its capital operations related to Magic Atom will be independent of the listed company [30] - International Composite Materials confirmed that electronic-grade glass fiber is a key raw material for PCBs [31] - Zhongyin Fashion plans to procure hardware simulation accelerators for 9.385 million USD [32] Group 11 - Haohai Biotechnology's shareholder plans to reduce his stake by up to 0.4337% [33] - United Optoelectronics plans to sign a framework contract with Lingzhi Cloud Creation for robot assembly services [34] - Qianfang Technology's major shareholder plans to reduce its stake by up to 1.5%, totaling no more than 2.36507 million shares [35] Group 12 - Xiamen Airport plans to acquire 100% of Zhaoxiang Technology for 1.193 billion yuan [36] - Tuoshan Heavy Industry plans to acquire 51% of Xin Kaiyuan for 219 million yuan [38] - Shenkai Co. plans to repurchase shares worth between 40 million and 80 million yuan [39] Group 13 - Hushun Co. plans to invest 3.3 billion yuan in a high-end PCB production project [40] - Zhengzhou Bank appointed Wang Sentao as vice president, pending regulatory approval [41]

昊海生科(688366.SH)发布公告，楼国梁因自身资金需要，计划自公告披露之日起3个交易日后3个月 内，通过集中竞价和大宗交易方式合计减持不超过100万股的公司股份，占公司总股本的比例不超过 0.4337%。 ...

智通财经APP讯，昊海生科(688366.SH)发布公告，楼国梁因自身资金需要，计划自公告披露之日起3个 交易日后3个月内，通过集中竞价和大宗交易方式合计减持不超过100万股的公司股份，占公司总股本的 比例不超过0.4337%。 ...

Summary of Key Points Core Viewpoint - Multiple shareholders across various companies are planning to reduce their stakes, indicating potential shifts in ownership and investor sentiment in the market [1]. Shareholder Reductions - **Qianfang Technology**: Hangzhou Haoyue plans to reduce its stake by up to 1.5% [1] - **Caicai Co., Ltd.**: Mingpai Industrial intends to reduce its stake by no more than 3% [1] - **Jingwei Co., Ltd.**: Directors and senior management plan to reduce their holdings by a total of up to 1.53% [1] - **Huitong Energy**: Shareholder Ningbo Hu plans to reduce its holdings by up to 2.0628 million shares [1] - **Huakang Clean**: The actual controller and its concerted actors plan to reduce their stake by no more than 3% [1] - **Dema Technology**: Shareholder Zhu Guangkui intends to reduce his stake by no more than 3% [1] - **Laisentongling**: Oulu Star Diamond plans to reduce its stake by up to 3% [1] - **Huibo Technology**: Huang Song plans to reduce his stake by no more than 1% [1] - **Haizheng Materials**: Sinopec Capital plans to reduce its stake by no more than 1% [1] - **Wuhai Biotechnology**: Lou Guoliang plans to reduce his holdings by a total of up to 1 million shares [1] - **Bofei Electric**: Shareholders Haining Yunge and Haining Jucheng plan to reduce a total of 2.3213 million shares [1] - **Dayuan Pump Industry**: Shareholder Han Yuanfu plans to reduce his stake by up to 5.595 million shares [1] - **Nanwei Software**: Shareholder Qizhong Shiyuan has already reduced his holdings by 4.934 million shares [1] - **Haige Communication**: Shareholder Yang Haizhou plans to reduce his stake by up to 4 million shares [1] - **Fuda Alloy**: Controlling shareholder Wang Dawu plans to reduce his stake by no more than 3% [1]

（文章来源：证券日报） 证券日报网讯 2月12日，昊海生科发布公告称，楼国梁拟于2026年2月26日至5月25日通过集中竞价及大 宗交易减持不超过1000000股，占公司总股本230561595股的比例不超过0.4337%，减持价格依市场确 定。 ...

Summary of Key Points Core Viewpoint - Haohai Biological Technology (688366.SH) announced that Mr. Lou Guoliang plans to reduce his holdings in the company due to personal financial needs, with a maximum reduction of 1 million shares, accounting for no more than 0.4337% of the total share capital [1] Group 1 - Mr. Lou Guoliang intends to reduce his holdings within three months from the announcement date [1] - The reduction will be executed through both centralized bidding and block trading methods, with a maximum of 1 million shares to be sold through each method [1] - The selling price will be determined based on the secondary market price [1]

Group 1 - The core viewpoint of the article highlights the recent share buyback and increase plans by certain companies, alongside the share reduction announcements from several others [1][3]. Group 2 - Chuzhou Development's controlling shareholder proposed to repurchase company shares worth between 100 million to 200 million yuan [3]. - Hainan Highway, the second-largest shareholder of Hainan Airlines Group, plans to increase its stake in the company [3]. - Wang Wei, the actual controller and director of Youkeshu, intends to increase his shareholding in the company [3]. Group 3 - Several companies announced share reductions, including: - Qianfang Technology, where shareholder Hangzhou Haoyue plans to reduce holdings by no more than 1.5% [3]. - Fuda Alloy, with controlling shareholder Wang Dawu intending to reduce holdings by no more than 3% [3]. - Dazhu Laser, where controlling shareholder Dazhu Holdings plans to reduce holdings by no more than 0.9672% [3]. - Dayuan Pump Industry, with shareholder Han Yuanfu planning to reduce holdings by no more than 3% [3]. - Huakang Clean, where the controlling shareholder and actual controller plan to collectively reduce their holdings [3]. - Jingwei Shares, with directors planning to reduce holdings by no more than 1.53% [3]. - Haizheng Materials, where shareholder Sinopec Capital intends to reduce holdings by no more than 1% [3]. - Huibo Energy, with shareholder Ningbo Huitong planning to reduce holdings by no more than 0.99999% [3]. - Other companies also announced similar reductions, including Caibai Shares, Nanda Optoelectronics, and Haohai Biomedical [3].

昊海生物科技(06826)公布，楼国梁先生因自身资金需要，计划自本公告披露之日起3个交易日后3个月 内，通过集中竞价和大宗交易方式合计减持不超过100万股的公司股份，占公司总股本的比例不超过 0.4337%，其中，通过集中竞价方式减持不超过100万股，通过大宗交易方式减持不超过100万股。减持 价格将根据二级市场价格确定。 ...